%PDF-1.7 % 12 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20250205180858+01'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 13 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 5 0 R ] /PZ 1 >> endobj 13 0 obj <> stream xݒGrudknؒpW{bzf aYC ?ϩ+Rȡ(Q42ˮ.YH ~o>j3]O??_z"SOteALß.ǟj7=O_q7Ro;f{pI\f{^T*:7g+ϔo<k[~ZAwnڠP|T ʯzVƞxK﷝tY۩=l/vx>W/TΟ͵ak~wauVl?Bﷱnli]7ۻ~Y+l;w{[|wjFca64:1acOouܡ헫Ggϗs[=Ga`G? z_8 ~D r餇ۗ'jޠQ^kTڱlR WWI8k7/G6q}q8Ux:Xyv,PҬh]jb&Y0lx,.kl;^- 3QOJ 㶝汾$UtWOsn'׻E|𞢆aRr8+io}4YA1jvl,S6bAv?Wh+Z!"ű dێ!+SbWѠ 䳰,r;d f O%*/V>U~fƩANA5bbYTz ZÕlIJ~yuX.4,g}_HPpiU(-sĄ6lKL\KXp%+D%Ϲ"K W. K V.rX\K(K>L%+$%&5.rxK s 3.X$\B\b$@\b$N\Rz.|%%AU<g\2V$2%%P<K(q ErI-{K(0 =F.I2d_g\B!$һ%:($K.+q 0D%^r KLl\z.aq K@\ONPd"*d%&4.]E.\H.x%7.=@\b%@\wo\{.L.ɒK V.#%V\K(Jҕ}s 3.Xw/r erI\K(^ "$uJ;K1K(K4߸$\&q ErIUKhDr\B\a7.=wϸ9%:%|s =K(KL7\`x-w% Qr﹄Q~%θ`aoncכf_t7<'j~|߬7zg-7wl)]"Γq6(bxLjga\>Q2{]҇O}0B͇4|PbĿhK kf#Z_Kk|1nG/"kBhV-|ϥ.Aq:J`Z^9׽̟pkբvH%l6_f yjPUD3v _zXku2X S_/cX.5<尓>xj`\%jY!+EVvX|M]YJq64yOca~Ew@\Ҕҹ6_o7wuGzz-9gМٱt_xIo{wY̒IśsW2l01m#LMс[uߔ}&Q2J(IR=X+SNEɜb12XWX]$>Q2~ _T .(W13_ֽy49E-*\M,bW2ƺtlVE d^e;d^6UїltW2 &'Q2J'U4dߕk/`VPFG:Q}p+WA"JՑrpVQdɼz\Eɼz-MQrր ̱\Ƈ⬨7aJ5Mʼny\+qj;gݴUxjv ,Ltv%sݞn a[8& ,w%sAAXˆ \dN7]خq5ҡk^Jh(8tʧΑ `mJzL{%32\4+CtXW2O ]sLX sY2r 1&Ӆ3W+.%*Qr-PڑcCb! ڮd^e(9PH/U;i}aF˵Mm}a9o\0\YL 9(9YFD9M,RW2 t1cbH%0 t0xcm&D#ha'JNى68M0y j,Cu1x'%(*&y>vZ 4F6Bw֑s=t5hz9lcV_ 7ZoL|.6w %LBT??u6Q˗*кֽC=py/WbEX5g5>:jW{w"Yr=h3h_kIrnr>Hڪiu>Orv/܃眖ǕGgڃ_[ze'W3=q ~_9 EWt=Q.~$) \\E%W_.Y ~ r<܃_}}$Ǧ$3E24IoPdJ^2+f ~/e?Ρ<)IcEC^pnb{lZ}@t+ \0i,tôf0379YGM0 {Hvp.|'tR8L4."ڕ99iNj! 0p>6kwsrW_hq4"R s\WާqԍN8\L؁_}$7plT_c1t Q]|ˡ` 48E :G8?de8CҸЧ z+"F"_ t*bX~]-e0(UM% P /GNC5{aZs=c Q7ՖO E43M)޶+:<4gG-&c$γbr/l~1Q"~e'ӻ1e,uB48vU91sjcJu]";x.Ai7Km2n#aҊG1E3&{vԜGf/P%&ţ61MthxVN2,ˊFgʻO#'[.=&4jwyLF*9hv\q]p\W]z4{?}@[b5]"ňQ`P"WΎА[7UEDZ[|8B<\34xx f ɲ(LJG/v4o@CܷsB!o ^kbCf w] 7w!/" `Th7=j'ܮKHzԂnii0*+IPxdPCo} Z>u[jϷw ƤMIULтoib "SG b㲑3ܟ;  vz 8v\K_E5AUh2ztj(OɃ0# e"ZGe$lpp&: IFrxyx`r;\ar7hcAlrģ܋ 3o>pZfow"\b@s|ODXSCÇ X 5'l[F'NJɞf|:l]:5s|?S斖1EppTU<@ coǹ~߁Z"8I`e{8 PsʾYG>@Y`J_Z-f"j4s=5=m`J }?P}GtWOt,f`]o1M]Rݜnd.96͑-)?:.inS_R ~h] +.?5#_BUV?Qvps Af|bY/}35柳9iܻ^3!9OG5΀Ѵ$8#h'r4h%pF|5~4L܈3a@rq| gD{PE*!G3Έh gPK| gD.!wT- rj3x|VӘk3(j3hS9@-p/~=O8Ro7uA1ղ|K^3Ǝnjދ~= F6{1V&F܎{ 0jܮb r3"_s> p3|O (9j'Bw<<3"? jX4;|yۄΈs4>.8 g@(w:f8*ZO9 h)||<48{Pho%pIZ>Ψj{|ops~s3Q,Vrk3=Π} gP+g 9d{ }TqEn@ZohF-Bs'%s1 zZͥ~Ǝ; Ƙ =3]c@輠.9Ψoo|u|Swm8;{r=Q 7TX aWt~ endstream endobj 14 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20250205180858+01'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 15 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /PZ 1 >> endobj 15 0 obj <> stream x\ے6}WUI@y-\$}8S$CR3ol{ǹ0θliZ` 8iT]3>weWKoͽGOdO/{ |NQ0xx-w죋_$I˾՛&ǣsMW`Iv4rY"S|)։fk%3M5lYomֶ5WUaClY?YYiTx`fG6n-[W5]uk6~.>)|5C^TqU[귟/'+{D_wȉwu>/Z,dݙXD( Uƕv$)"uBT8aDdt UT<*x;LLd\g;b]LAԲH$(_ЀOi݅w%qlm81.,M{GIJ(`>ӭ!'ƂϷe C J7h$L0VO L戟^A4:LGw!A* 5^{)<^Z-CIo`ÒW-`Lr˺y}wlE\Ygq܆hC\Uo -P߁Ydk;r)v]^MPds5Vp.C Z2˜\s\*lT,a놉? eb)=QvW-$<8lkM=nKFUs٢:wU {KS/a$&=J9X ޮcuВV8pYz鮂BA HS˥Vق.4צT|W ٙb>}^we{( ~"HH}Sa5kڑnF.\ 滶>W@3v7,~a9e'=gMnvU'cй+jy; a]W$Z/a6P~c%s-2A;ʤ8H"Jt3P.wjU[c5dsOroqY_FQZ߶b~)E 8vq'5Uq9Y_c:=pDxR>fsz $8+8Q/`:?`}Vjzン"*QV e@/= oF<`NENڎPT !JuP kQӷ=;/@N⮺$ }rIjg GJ=<6"(6RP?`c}۔[긍XרuzlY]:H&>O?: .!pcd!Ɵ/y{ڗD|=XۡF'Z'R`0)HO:؟E UCަYacHpۡ.ؿv3, ڿ];yŃ?tM{ )dFUb ȱۑGHuѳ3t-[:xY2cE ~ZeWwQ*8XIͦ6oz>RN#ǐ8R -K7ǵ2\QWވ#_ { {;FZ[߾Fk{+!]| m-6Ssp6_LYEh3"Rt ne]4cH6B^rj^@놭LW46þqNޙ6fg,?}.ɰ.:mCtoߪHÑhbYLкp&kio.lc\i}Aowgn 0δ)){$M W "dEx UTs\YPDz m`Ughfm!>T06v1j$>;Ne~/s>KxXSIlPIlɷסv lVz" Q| [Ճ}Yj֙71+4uA{u= o/2K&l79I&yr2%NSc}2}{L( endstream endobj 16 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20250205180858+01'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 17 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 6 0 R 7 0 R ] /PZ 1 >> endobj 17 0 obj <> stream xrHy-$[SXvjԶ&4fF>ƾF>'$` ȚOw=.=`.}\5 o^?~9?[8;?Ox#ދ=Mz2>cxh9::lFǢ? ]y]zapû(pӹ@9F 0/Pb 8` &| |X,'MX7V/(RR)P06 giЮt.HT<rmC'\!vF\Q4SbJka,-IYxB!,x>HT0:Sf`A^`D2%"Ŝ& jV&Ƙr18LƊ@H0D`XR =֔HQ>hSQUfBoy@&492i Jy3A )l 8%Rv2@Ef`Zd5$ϵV"j-e"bXl%T3ysńpqGɖ^**S&N,2WL3.yEE2YH*|LyN2cZ@h,L|kݸqexvxF̉(l+ *g@2y #ΧEyT}nx%筴q&o bwJuuvSj\LF0Bti+gHDΫ&Ry%rUjY6JDI>1^\jo#S[Z{5ΒuW =N:X7kH`NJ^`8fkT.Y!6>˲2;NA6Iu?:AƖK*u U;9K9iQQX!iJb3yB:$yZ <1:/M4fցQ2ۺqT:SZoɭE:fs8u{_Ema&s3ɲ'C'tN~L#FRVrZUi2MkA-!P. ݴ} %|1ۙ[4)l9 S=Juj `QM\$U2#! QN&) -ܷcynx]d*̈́gkxJըy3l6%մlNݺE}^0WHq?E ܶvT)AYE_&z@ۦzLcH) ڸ%2U,\߹4xګۋŽj7~ig+zl?q\_"Im endstream endobj 18 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20250205180858+01'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 19 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 8 0 R 9 0 R 10 0 R 11 0 R ] /PZ 1 >> endobj 19 0 obj <> stream xZMSI+*dG@?<'06^{90JݚVkLߗUH1Br`)^̒ 8l8{/ix^Kg6ʫ7! 6Xɮ07LO{xVxlt`-y,|>9_7]M[B/BKf/sN8v0ou~3y~*q*4Q q;./h>S )e싙[syΔ\rhRŴb}M?i9(ףu/GvԶ^`V%b|v[I ࣋{*ofgN;jAJ[Ux}m9We*l>lEXLΣyc^;fsOuY՛IG6ЬHQX0J)`~|9} 4U=ba2\= M1'OFOz?dMIɹ|V:}1!gq,a4e=AbiIVSM1>)T u ]E'qqM0a-0/&q]3j8҉B4j*- %Q}4"?M+- gS|yl5c* DOsBK"pG|ͷaBr"(DAeiH"PJ%t`U4 L!J:x˃Am14(R';-VbVBZDpF cu=ـ䠒c>8o;<^H#ȍn! V&BIC]n$fJ\%`ņN.L9itWA1y `L`뜉ku0|Uv4OD-l2 }0ٮ10h`ANAK^bmZd"BcGZ :+Ϡq>alƵؕ [Y͛) ]$Pė-$$25W@1,5Bp @^ b TNsOo__L3 endstream endobj 1 0 obj << /Type /Pages /Kids [ 12 0 R 14 0 R 16 0 R 18 0 R ] /Count 4 >> endobj 3 0 obj <> endobj 4 0 obj <> endobj 20 0 obj <> /Resources <> /Font <> /ExtGState <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 848 >> stream xWmO0^c$H (똆AIC|J(ՠemIªل׹Gdw7>9<GkDžaW$<"H2|R(29:9$^-e>..y.Gd:|VCd` ')ɮB(TEҒ %% E֙ J,$BDO&D>MH0-6=C.h&CfR\ X+b :Nic*k+ p.}&xs|"8 n,v )W-6o=߸hNftK:M[ۀr!e\KeAky$RP<⺍pxup8>H  M{qI3_w,縲eGfNՑmna.hȓjYU,b\2OuyZ6#sC͚3gkriӲ ly#4]kDfu |w*lm O镸080iIsӵһ%7/i\XJ.̚5K5jM9aq'wqh%Q*i gyQ(p]5'CԫkSuRCln_*9{.+|FAqp-Pg*O hsRՎSJ&`1U$GBHB-K5NюG~?Rh#%SkC3a-r"7αը $O+ o endstream endobj 27 0 obj <> /Resources <> /Font <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 220 >> stream x]M0EԅIтUqEڅ̿7.:Ãۼ{?bb_"YiFgTT&IF |Sk=(PB{U!Z]?s{7mCwoTbV DH)iRHK 4 A&J0;*UaVj&T]Y-v|OɄzUx5>w I endstream endobj 26 0 obj <> endobj 25 0 obj <> endobj 32 0 obj [250 0 0 0 0 0 0 0 0 0 0 564 0 333 250 0 500 500 500 500 500 0 500 500 500 500 0 0 0 0 0 0 921 0 0 0 722 611 556 722 722 0 0 0 0 889 0 0 556 0 667 556 0 0 0 0 0 0 611 0 0 0 0 0 0 444 500 444 500 444 0 0 500 278 0 500 278 778 500 500 500 0 333 389 278 500 500 722 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 ] endobj 31 0 obj <> endobj 24 0 obj <> stream x  Om7^ Oa endstream endobj 33 0 obj <> stream x nH@o endstream endobj 23 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 22 0 obj <> stream x  Om783  endstream endobj 34 0 obj <> stream x nH@paX endstream endobj 21 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > endobj 36 0 obj [250 ] endobj 35 0 obj <> endobj 29 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 28 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > /XObject <> >> endobj 5 0 obj <> /H /I>> endobj 6 0 obj <> /H /I>> endobj 7 0 obj <> /H /I>> endobj 8 0 obj <> /H /I>> endobj 9 0 obj <> /H /I>> endobj 10 0 obj <> /H /I>> endobj 11 0 obj <> /H /I>> endobj 37 0 obj << /Title (Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevail) /Author (Daiichi Sankyo) /Subject (Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevail) /Creator (TCPDF) /Producer (TCPDF 6.7.5 \(http://www.tcpdf.org\)) /CreationDate (D:20250205180858+01'00') /ModDate (D:20250205180858+01'00') /Trapped /False >> endobj 38 0 obj << /Type /Metadata /Subtype /XML /Length 4967 >> stream application/pdf Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevail Daiichi Sankyo Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevail 2025-02-05T18:08:58+01:00 TCPDF 2025-02-05T18:08:58+01:00 2025-02-05T18:08:58+01:00 TCPDF 6.7.5 (http://www.tcpdf.org) uuid:51466bf2-b0a6-3adf-81a4-d8cfaa1963a7 uuid:51466bf2-b0a6-3adf-81a4-d8cfaa1963a7 http://ns.adobe.com/pdf/1.3/ pdf Adobe PDF Schema internal Adobe PDF Schema InstanceID URI http://ns.adobe.com/xap/1.0/mm/ xmpMM XMP Media Management Schema internal UUID based identifier for specific incarnation of a document InstanceID URI http://www.aiim.org/pdfa/ns/id/ pdfaid PDF/A ID Schema internal Part of PDF/A standard part Integer internal Amendment of PDF/A standard amd Text internal Conformance level of PDF/A standard conformance Text endstream endobj 39 0 obj << /Type /Catalog /Version /1.7 /Pages 1 0 R /Names << >> /ViewerPreferences << /Direction /L2R >> /PageLayout /SinglePage /PageMode /UseNone /OpenAction [12 0 R /FitH null] /Metadata 38 0 R >> endobj xref 0 40 0000000000 65535 f 0000015642 00000 n 0000052754 00000 n 0000015723 00000 n 0000015829 00000 n 0000052894 00000 n 0000053148 00000 n 0000053380 00000 n 0000053612 00000 n 0000053903 00000 n 0000054167 00000 n 0000054588 00000 n 0000000015 00000 n 0000000485 00000 n 0000006561 00000 n 0000007013 00000 n 0000010645 00000 n 0000011121 00000 n 0000012893 00000 n 0000013383 00000 n 0000015940 00000 n 0000027624 00000 n 0000026831 00000 n 0000019161 00000 n 0000018601 00000 n 0000017748 00000 n 0000017692 00000 n 0000017160 00000 n 0000044254 00000 n 0000036584 00000 n 0000036124 00000 n 0000018349 00000 n 0000017934 00000 n 0000018908 00000 n 0000027312 00000 n 0000036332 00000 n 0000036309 00000 n 0000054806 00000 n 0000055711 00000 n 0000060761 00000 n trailer << /Size 40 /Root 39 0 R /Info 37 0 R /ID [ <51466bf2b0a63adf81a4d8cfaa1963a7> <51466bf2b0a63adf81a4d8cfaa1963a7> ] >> startxref 60971 %%EOF

Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevail

  • Survey with 7,750 participants highlights the urgent need for more and improved access to information about breast cancer and metastatic breast cancer across Europe
  • Results emphasise lack of knowledge of breast cancer severity, age of diagnosis and biomarker status 

Munich, Cambridge – (January, 22 2025) – A new survey sponsored by Daiichi Sankyo and AstraZeneca reveals that there is a need for more readily available information on breast cancer, with results revealing misconceptions and a lack of public awareness. The survey conducted across the major five European countries with 7,750 respondents found varying levels of public knowledge about breast cancer and metastatic breast cancer*.1

Key results from the survey include:

  • Recognition of challenges in breast cancer: More than one-third of respondents across all countries recognise that breast cancer has not been overcome, especially in Spain (49%) and the UK (46%) where the majority of respondents do not believe in a chance of cure.
  • Demand for readily available information: 88% of respondents expressed a desire for more information about breast cancer. Respondents’ top three areas of interest were information on new treatments, life expectancy and quality of life. 43% expressed concerns about the ease of understanding medical information on breast cancer. 
  • Age misconception: Half of the participants believe age does not impact the risk of developing metastatic breast cancer, although increased age is a significant risk factor.
  • Regional awareness gaps: Across Europe, awareness of metastatic breast cancer varies, with 93% of Spanish respondents having some understanding or certainty about the disease, compared to 59% in the UK.
  • Biomarker awareness: Three quarters of respondents are unfamiliar with the concept of a biomarker, with awareness being highest in Spain (34%), followed by Italy (31%), Germany (23%) and lowest in France and the UK (both 18%).

Better awareness and understanding of breast cancer can lead to earlier detection and improved survival rates2
In Europe, approximately 558,000 new cases of breast cancer are diagnosed each year, resulting in about 145,000 deaths.3 Even with established breast cancer screening programmes, it is estimated that 30% of people diagnosed with early-breast cancer will progress to develop metastatic disease, with 5% to 10% of breast cancers being diagnosed as metastatic (stage 4) at initial presentation.4,5 

Access to accurate and easy to understand healthcare information is critical, as increased awareness can lead to earlier detection and improved survival rates. Better understanding of metastatic breast cancer is essential for patients, families and caregivers to best manage care.2

“People should not have to experience breast cancer to be made aware of its impact and symptoms,” says Dr Fatima Cardoso, President at ABC (Advanced Breast Cancer) Global Alliance, Lisbon, Portugal. “Earlier detection of cancer can save lives. It is vital that information about breast cancer is easily accessible, readily available and easy to understand to help improve patient outcomes through their care and treatment. Increasing patient understanding of their cancer biomarkers, is essential to their care. Biomarkers provide important biological information about cancer severity and prognosis, are crucial to provide individualised treatment options and assist physicians in monitoring the cancer during and after treatment. Understanding biomarker status enables more personalised medicine approaches, targeting cancer cells more specifically and improving patients’ quality of life.”

“The results clearly show that despite the high incidence rate of cancer in Europe, there are still many misconceptions and information gaps,” says Dr Markus Kosch, Head of Europe and Canada Oncology Business Division, Daiichi Sankyo. “Greater public understanding of breast cancer and metastatic breast cancer is needed to empower the European population to seek the support they need at the earliest opportunity when they need it. Daiichi Sankyo and AstraZeneca are committed to collaborating with patient advocacy groups to provide reliable information and resources. It is crucial that everyone has access to potentially life-saving information and knows exactly where to find it. This is not just true for breast cancer, but for all cancers.”

“These insights, coupled with the compelling statistics regarding the ongoing prevalence and impact of breast cancer reinforce that global leaders, policy experts, clinicians and patient advocates must continue to work together to prioritise breast cancer, especially metastatic disease,” says Greg Rossi, Senior Vice President Oncology, Europe and Canada, AstraZeneca. “Through our alliance with Daiichi Sankyo, we are committed to raising awareness and breaking down barriers to ensure that every patient with breast cancer has access to the right care and information about their diagnosis.”

About the survey
The online survey, sponsored by Daiichi Sankyo and AstraZeneca, gathered insights from respondents across five European countries: France, Germany, Italy, Spain and the UK. There were around 1,550 participants from each country, with an average gender distribution of 52% female and 48% male. Participants were aged 18-years and older and the survey results were collected over 10 days in October 2024.

About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialise a antibody drug conjugate (ADC) in March 2019 and a second ADC in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. 

About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.
With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales and marketing. We supply around 36 different medicines to the NHS.
For more information, please visit www.astrazeneca.co.uk.
 

Media contacts:

Simone Jendsch-Dowé

Daiichi Sankyo Europe GmbH

simone.jendsch-dowe@daiichisankyo.com

+49 176 11780822

 
References

1 Breast Cancer Awareness Survey in Europe" conducted in October 2024 for the Daiichi-Sankyo | AstraZeneca Alliance with a sample size of 7,750 respondents across Germany, France, Europe, Italy and Spain.

2 Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. Lancet Glob Health. 2018 Aug;6(8):e885-e893.

3 GLOBOCAN. Europe. Cancer Today 2022. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/908-europe-fact-sheet.pdf. Accessed January 2025.

4 Seely JM. Progress and Remaining Gaps in the Early Detection and Treatment of Breast Cancer. Curr Oncol. 2023 Mar 8;30(3):3201-3205. 

5 Europa Donna. Metastatic Statistic Guidelines. Available at: https://www.europadonna.org/metastatic/statistics-guidelines/. Accessed January 2025.